BLMH/Bleomycin Hydrolase Antibody [Unconjugated]

Western blot shows lysates of SH-SY5Y human neuroblastoma cell line and Neuro-2A mouse neuroblastoma cell line. PVDF Membrane was probed with 1 µg/mL of Human BLMH Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6200) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for BLMH at approximately 53 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.

• Reactivity: Hu, Mu
• Applications: WB
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Unconjugated
• Concentration: LYOPH

BLMH/Bleomycin Hydrolase Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human BLMH
  Ser2-Glu455
  Accession # Q13867
• Specificity: Detects human and mouse BLMH in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Gene: BLMH
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.2 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for BLMH/Bleomycin Hydrolase Antibody [Unconjugated]

• BHBMHBLM hydrolase
• bleomycin hydrolase
• BLMH
• BMH
• EC 3.4.22.40

Background

Bleomycin Hydrolase (BLMH) is a cysteine peptidase of the papain superfamily. It is named for its ability to hydrolyze the antitumor agent bleomycin and inactivate it (1). It has a papain-like catalytic triad (Cys-His-Asp) with optimum activity at neutral pH. In mammals it is expressed ubiquitously in all types of tissues and its expression is up‑regulated in many tumors. It is present in the cytoplasm as homohexameric protein of approximately 300 kDa. In addition to its aminopeptidase activity, it has homocysteine-thiolactonase activity. The normal physiological function of BLMH is not clear. BLMH inactivates bleomycin, a glycopeptide anticancer agent, by deaminating it (2). BLMH has been suggested to play a role in the generation of MHC class I-presented peptides (3 ‑ 4). Diminished BLMH activity may contribute to the pathology of Alzheimer’s disease (AD) (5 ‑ 6). It is inhibited by cysteine protease inhibitors such as N-ethylmaleimide, iodoacetamide, para-hydroxymercuribenzoate, and E-64.

1. Joshua-Tor, L. and S. A. Johnson (2004) in Handbook of Proteolytic Enzymes, Barrett, A. J. et al. eds. pp. 1197.
2. Schwartz, D. R. et al. (1999) Proc. Natl. Acad. Sci. USA, 96:4680.
3. Kim, E. et al. (2009) J. Immunol. 183:7379.
4. Towne, C. F. et al. (2007) J. Immunol. 178:6923.
5. Suszynska, J. et al. (2010) J. Alzheimers Dis. 19:1177.
6. Lefterov, I. M. et al. (2000) FASEB J. 14:1837.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: BLMH
• Uniprot:
  • Q13867()